The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Projected To Reach By 2030?
The market for calcitonin gene-related peptide (cgrp) inhibitors has experienced robust expansion recently. Projections indicate a rise from $3.14 billion in 2025 to $3.45 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. Historically, this growth can be attributed to factors such as the increasing occurrence of migraine disorders, the inadequacies of traditional migraine medications, expanding clinical evidence supporting the CGRP pathway, greater acceptance by neurologists, and advantageous reimbursement policies in mature markets.
The calcitonin gene-related peptide (cgrp) inhibitors market is projected for significant expansion over the coming years. This market is anticipated to reach $5.02 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. Factors contributing to this growth throughout the forecast period include the expanding population of chronic migraine sufferers, the broadening pipeline of oral CGRP inhibitors, a rising need for sustained migraine prevention, enhanced patient compliance with targeted treatments, and increased market penetration in developing regions. Key trends anticipated during this period encompass the wider acceptance of targeted migraine treatments, a notable movement towards prophylactic migraine management, a growing inclination for non-opioid options for pain relief, the proliferation of oral CGRP small molecule inhibitors, and heightened recognition and diagnosis of chronic migraine.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp
What Key Factors Are Affecting The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Demand?
The projected expansion of the calcitonin gene-related peptide (CGRP) inhibitors market is expected to be propelled by the increasing incidence of migraine. A migraine is defined as an intense headache, frequently manifesting as throbbing pain on one side of the head, and often accompanied by symptoms such as nausea, vomiting, and heightened sensitivity to light and sound. The rising prevalence of migraine is attributed to elevated stress levels, as sustained stress activates specific neural pathways. Calcitonin gene-related peptide (CGRP) inhibitors are instrumental in migraine management by offering a precise, preventative mechanism that is compatible with both acute and chronic care regimens. These inhibitors function by effectively blocking CGRP receptors, leading to a decrease in the frequency and severity of headaches, thereby improving patient well-being and daily functioning. For instance, in January 2023, a report from the National Library of Medicine, a US-based health information institution, revealed that the global prevalence of migraine ranges between 14% and 15%, contributing to 4.9% of the global disease burden. Therefore, the escalating prevalence of migraine is serving as a significant driver for the growth of the calcitonin gene-related peptide (CGRP) inhibitors market.
How Are Different Segments Classified In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Segment Analysis?
The calcitonin gene-related peptide (cgrp) inhibitors market covered in this report is segmented –
1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies
Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems
Which Trends Are Impacting The Progress Of The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
Key companies in the calcitonin gene-related peptide (CGRP) inhibitors market are concentrating on developing innovative products to gain regulatory approvals. This includes advancements in calcitonin gene-related peptide (CGRP) receptor antagonists designed to boost the effectiveness of migraine treatment, broaden their therapeutic indications, and offer more convenient administration routes, such as oral and intranasal forms. A calcitonin gene-related peptide (CGRP) receptor antagonist is a medication that blocks the calcitonin gene-related peptide (CGRP) receptor to impede pain signaling linked to migraines. For instance, in April 2023, AbbVie Inc., a US-based biotech company, secured approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) for the treatment of chronic migraine in adults. QULIPTA is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that functions by blocking calcitonin gene-related peptide (CGRP) receptors, which are implicated in the pathophysiology of migraine, thereby helping to prevent migraine attacks.
Who Are The Companies Driving Activity In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
Major companies operating in the calcitonin gene-related peptide (cgrp) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.
Get The Full Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Report:
Which Region Is The Top Contributor To The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market By Share?
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (cgrp) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market 2026, By The Business Research Company
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Peptide Based Metabolic Disorders Therapeutics Market Report 2026
Cc Chemokine Receptor Type 5 Market Report 2026
https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model